Summary

This article discusses the results of the Durability of Combination Therapy With Exenatide/Metformin Versus Conventional Therapy in New Onset T2DM study [NCT01107717] that evaluated the effects of a triple-therapy regimen versus stepwise add-on conventional therapy in patients with newly diagnosed type 2 diabetes. In this open-label study, 155 patients were randomized to triple therapy or stepwise add-on conventional therapy, with a goal of achieving an HbA1C of <6.5%.